Clinical Trial Update: Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea

View source ↗

Summary

This clinical trial update describes a regulatory post-marketing surveillance study of Secukinumab (Cosentyx) in Korean patients with hidradenitis suppurativa, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hidradenitis Suppurativa
• Juvenile Idiopathic Arthritis
• Plaque Psoriasis

Drugs mentioned

• Cosentyx (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Hidradenitis Suppurativa, Pediatric Plaque Psoriasis | Status: RECRUITING